Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Momenta Pharmaceuticals Announces Early HSR Clearance for Biosimilars Collaboration With Mylan
Globe Newswire

CAMBRIDGE, Mass., Feb. 10, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the global collaboration agreement executed by the Company on January 8, 2016 with Mylan N.V.’s subsidiary, Mylan Ireland Limited, to develop and commercialize six biosimilar candidates.

With the early termination of the applicable waiting period under the HSR Act, the collaboration agreement with Mylan is effective as of February 9, 2016.  Under the collaboration agreement, Mylan is obligated to pay Momenta a $45 million upfront cash payment within 30 days of the effective date.

Additional details regarding the collaboration can be found in Momenta’s Form 8-K filed with the Securities and Exchange Commission on January 8, 2016.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Sarah Carmody			
Momenta Pharmaceuticals		
Karen Sharma
MacDougall Biomedical Communications

Primary Logo

 Top of page